The Effects of IFN-β 1a on the Expression of Inflammasomes and Apoptosis-Associated Speck-Like Proteins in Multiple Sclerosis Patients

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2016 Apr 2

PMID 27032392

Citations 14

Authors

Saam Noroozi

Hossein Ali Ebrahimi Meimand

Mohammad Kazemi Arababadi

Nouzar Nakhaee

Gholamreza Asadikaram

Affiliations

Soon will be listed here.

Abstract

This study aims to evaluate the effects of treatment with IFN-β 1α on the expressions of NLRP3, NLRP1, NLRC4, and AIM2, as inflammasomes, and caspase-1, IL-1β, and IL-18, as the downstream molecules of inflammasomes, in a population of Iranian multiple sclerosis (MS) patients. In this study, 30 MS patients (22 women and 8 men) participated. Before receiving any medication and 6Â months after treatment with standard doses of IFN-β 1α 30Â mcg injected intramuscularly once a week, blood samples were taken and then the leukocytes isolated, total RNAs extracted, and complementary DNAs (cDNAs) synthesized. Gene expressions of NLRP3, NLRP1, NLRC4, AIM2, and ASC were evaluated at messenger RNA (mRNA) levels using real-time PCR method; for assessing caspase-1 at protein level, the Western blot method was used. The amounts of IL-1β and IL-18 were measured in plasma using enzyme-linked immunosorbent assay method. Analysis of the results before and after therapy with IFN-β 1α in all patients shows significantly decreased expressions of NLRP3, NLRC4, and AIM2. The plasma levels of IL-1β, after treatment with IFN-β 1α, were significantly decreased in the MS patients. Based on our results, it appears that NLRP3, NLRC4, and AIM2 play critical roles in the progression of MS, probably by mediating Th1 and Th17 responses. It seems that decreased expression of IL-1β is related to decreased production and also functions of inflammasomes.

Citing Articles

Inflammasomes in neurodegenerative diseases.

Wang Q, Yang S, Zhang X, Zhang S, Chen L, Wang W Transl Neurodegener. 2024; 13(1):65.

PMID: 39710713 PMC: 11665095. DOI: 10.1186/s40035-024-00459-0.

Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology.

Fan H, Fu Q, Du G, Qin L, Shi X, Wang D CNS Neurosci Ther. 2024; 30(12):e70135.

PMID: 39690733 PMC: 11652677. DOI: 10.1111/cns.70135.

Multiple sclerosis: the NLRP3 inflammasome, gasdermin D, and therapeutics.

Brint A, Greene S, Fennig-Victor A, Wang S Ann Transl Med. 2024; 12(4):62.

PMID: 39118955 PMC: 11304424. DOI: 10.21037/atm-23-1960.

Inflammasome Molecular Insights in Autoimmune Diseases.

Neamtu M, Bild V, Vasincu A, Arcan O, Bulea D, Ababei D Curr Issues Mol Biol. 2024; 46(4):3502-3532.

PMID: 38666950 PMC: 11048795. DOI: 10.3390/cimb46040220.

Inflammasomes in neurological disorders - mechanisms and therapeutic potential.

Ravichandran K, Heneka M Nat Rev Neurol. 2024; 20(2):67-83.

PMID: 38195712 DOI: 10.1038/s41582-023-00915-x.

References

Szabo G, Csak T . Inflammasomes in liver diseases. J Hepatol. 2012; 57(3):642-54. DOI: 10.1016/j.jhep.2012.03.035. View

Anderson G, Rodriguez M . Multiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin. Eur J Neurol. 2010; 18(5):680-5. DOI: 10.1111/j.1468-1331.2010.03257.x. View

McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7. DOI: 10.1002/ana.1032. View

Inoue M, Williams K, Oliver T, Vandenabeele P, Rajan J, Miao E . Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal. 2012; 5(225):ra38. PMC: 3509177. DOI: 10.1126/scisignal.2002767. View

Inoue M, Williams K, Gunn M, Shinohara M . NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2012; 109(26):10480-5. PMC: 3387125. DOI: 10.1073/pnas.1201836109. View

Graber J, Dhib-Jalbut S . Biomarkers of interferon Beta therapy in multiple sclerosis. J Interferon Cytokine Res. 2014; 34(8):600-4. DOI: 10.1089/jir.2013.0144. View

Jafarzadeh A, Bagherzadeh S, Ebrahimi H, Hajghani H, Bazrafshani M, Khosravimashizi A . Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern. J Mol Neurosci. 2014; 53(3):500-5. DOI: 10.1007/s12031-013-0214-2. View

Malhotra S, Rio J, Urcelay E, Nurtdinov R, Bustamante M, Fernandez O . NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain. 2015; 138(Pt 3):644-52. PMC: 4408432. DOI: 10.1093/brain/awu388. View

Qizilbash N, Mendez I, Sanchez-de la Rosa R . Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis. Clin Ther. 2012; 34(1):159-176.e5. DOI: 10.1016/j.clinthera.2011.12.006. View

10.

Freeman L, Ting J . The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem. 2015; 136 Suppl 1:29-38. DOI: 10.1111/jnc.13217. View

11.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J . Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41. DOI: 10.1038/nature04516. View

12.

Shaw P, Lukens J, Burns S, Chi H, McGargill M, Kanneganti T . Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. J Immunol. 2010; 184(9):4610-4. PMC: 3001131. DOI: 10.4049/jimmunol.1000217. View

13.

Jha S, Srivastava S, Brickey W, Iocca H, Toews A, Morrison J . The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci. 2010; 30(47):15811-20. PMC: 6633756. DOI: 10.1523/JNEUROSCI.4088-10.2010. View

14.

Panitch H . Interferons in multiple sclerosis. A review of the evidence. Drugs. 1992; 44(6):946-62. DOI: 10.2165/00003495-199244060-00004. View

15.

Jafarzadeh A, Ebrahimi H, Bagherzadeh S, Zarkesh F, Iranmanesh F, Najafzadeh A . Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: a comparison between patients and healthy women. Inflammation. 2013; 37(2):604-10. DOI: 10.1007/s10753-013-9775-z. View

16.

Cucci A, Barbero P, Clerico M, Ferrero B, Versino E, Contessa G . Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose. J Neuroimmunol. 2010; 226(1-2):150-7. DOI: 10.1016/j.jneuroim.2010.05.038. View

17.

Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I . Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011; 34(2):213-23. DOI: 10.1016/j.immuni.2011.02.006. View

18.

Inoue M, Shinohara M . The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes. Immunology. 2013; 139(1):11-8. PMC: 3634535. DOI: 10.1111/imm.12081. View

19.

Lalor S, Dungan L, Sutton C, Basdeo S, Fletcher J, Mills K . Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol. 2011; 186(10):5738-48. DOI: 10.4049/jimmunol.1003597. View

20.

Millward J, Lobner M, Wheeler R, Owens T . Inflammation in the central nervous system and Th17 responses are inhibited by IFN-gamma-Induced IL-18 binding protein. J Immunol. 2010; 185(4):2458-66. DOI: 10.4049/jimmunol.0902153. View